...award speaks to the importance of this study...
Scottsdale, Arizona (PRWEB) September 08, 2012
QualityStocks would like to highlight AxoGen, Inc., a publicly traded regenerative medicine company, providing products and technologies for peripheral nerve reconstruction and regeneration. Its product portfolio comprises Avance Nerve Graft, an allograft nerve for bridging nerve discontinuities; AxoGuard Nerve Connector, a coaptation aid that allows for the close approximation of severed nerves; and AxoGuard Nerve Protector, a surgical implant that protects nerves during the bodys healing process after surgery.
In the company’s news Friday,
AxoGen announced that its submission on findings from the RANGER™ Registry, an on-going study for the Avance® Nerve Graft, was selected for an Outstanding CTBS Abstract Award and was accepted for poster display at the American, Keystone, Colo., September 8-10, 2012.
Titled “Clinical Results from a Multicenter Registry Study on the Use of Processed Nerve Allograft for Sensory, Mixed and Motor Nerve Repairs,” the abstract demonstrates the successful recovery of 87 percent of cases involving 66 patients and 92 injuries suffering peripheral nerve repair. The analysis shows no reported graft related complications, tissue rejections, or adverse events.
According to Erick DeVinney, director of Clinical and Translational Sciences for AxoGen, the RANGER Study is the largest, multicenter observational study in peripheral nerve repair, and that receiving the Outstanding CTBS Abstract Award reflects the value of the outcome of the study.
“We are very pleased to see these levels of meaningful recovery across sensory, motor and mixed nerves,” DeVinney stated in the press release. “The selection by AATB for an Outstanding CTBS Abstract Award speaks to the importance of this study in demonstrating outcomes from peripheral nerve injuries repaired using processed nerve allograft.”
AxoGen said its Avance Nerve Graft is the only commercially available processed nerve allograft for surgically repairing peripheral nerve discontinuities.
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit http://www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.